Find the right fit for you - faster
Get tailored insights about working at Transplant Genomics in one quick step.
Transplant Genomics Snapshot
Biotech & PharmaceuticalsIndustry
Transplant Genomics aims to improve transplant outcomes through molecular diagnostic tests that detect early signs of graft injury, differentiate among actionable causes, and enable optimization of therapy.
In the United States alone, nearly 40,000 organ transplants are performed annually, with kidney, liver, heart, and lung being the most common. Living donor and deceased donor organ transplants have substantially improved the quality of life for hundreds of thousands of patients. However, despite continuous advancements in surgical and medical practices, incidences of acute rejection and chronic damage of transplanted organs remain a significant problem to post-transplant patient health. Acute rejection, including subclinical acute rejection (SubAR), can negatively impact patient quality of life and lead to chronic rejection — minimizing allograft survival and requiring re-transplantation or other interventions.
Since 2014, Transplant Genomics, Inc. has been committed to improving organ transplant outcomes through non-invasive molecular diagnostics that detect early signs of allograft injury, differentiate among actionable causes, and optimize therapy.
The standard protocols for post-transplant monitoring rely on late-trailing indicators of graft function or painful, expensive, and invasive surveillance biopsies. These tests may not indicate imminent rejection until the allograft is significantly damaged, leaving clinicians and patients fewer options to improve organ health before more severe complications occur.
Transplant Genomics’ extensive development pipeline includes non-invasive diagnostic and predictive tests for kidney and liver graft dysfunction, the use of multiple sample types (e.g. blood and urine) and technology platforms (e.g. NGS, qPCR, and microarrays), companion diagnostics for immunosuppressants, and immune status tests.
Transplant Genomics is a team of passionate and committed scientists, clinicians, laboratory technicians, and business professionals who strive to improve the quality of life for transplant recipients. We are committed to developing innovative tests and technologies that provide an accurate and actionable notice of graft injury, giving transplant care teams the best opportunity to address complications early and preserve organ health and function.
We share a set of core values that infuse everything we do:
We put patients first.
There is a human life behind every specimen we test in the lab. Transplant recipients are our family, friends, and neighbors. We calibrate everything we do by asking, “Will this help get accurate and timely test results into the hands of a clinician and their patient so that they can make the best decisions about their patient’s health?”
We are grounded by science.
We partner with leading research institutions, transplant centers, and higher-education colleges and universities to ensure our work is backed by scientific validity and clinical utility.
We hire talent and nurture our team.
We actively seek out and employ people with demonstrated scientific, operational, and business success who are passionate about improving the quality of life for transplant patients. As a team, we communicate and collaborate, challenge each other, and support each other in fulfilling our mission.
We celebrate our wins.
Helping patients experience better transplant outcomes is a success worth celebrating! We recognize, internally and externally, the strategies, activities, and results that improve patient care.
We are committed to our customers’ success.
We partner with the hospitals and clinics that use our tests, providing the education, tools, and support they need to be successful. We never lose sight of the connection between the tests we offer and the patients who need them.
In 2019, Eurofins Scientific acquired Transplant Genomics as part of its Clinical Diagnostics portfolio of laboratories. Eurofins, through its subsidiaries, is the world leader in food, environment, pharmaceutical, and cosmetic products testing, and in agroscience CRO services. Eurofins is also one of the global independent market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences, and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty esoteric and molecular clinical diagnostic testing in Europe and the USA.
With over 50,000 staff in over 50 countries, operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin, and purity of biological substances and products, as well as for innovative clinical diagnostics. Eurofins’ objective is to provide its customers with high-quality services, accurate results on time, and expert advice by its highly qualified staff.
In the United States alone, nearly 40,000 organ transplants are performed annually, with kidney, liver, heart, and lung being the most common. Living donor and deceased donor organ transplants have substantially improved the quality of life for hundreds of thousands of patients. However, despite continuous advancements in surgical and medical practices, incidences of acute rejection and chronic damage of transplanted organs remain a significant problem to post-transplant patient health. Acute rejection, including subclinical acute rejection (SubAR), can negatively impact patient quality of life and lead to chronic rejection — minimizing allograft survival and requiring re-transplantation or other interventions.
Since 2014, Transplant Genomics, Inc. has been committed to improving organ transplant outcomes through non-invasive molecular diagnostics that detect early signs of allograft injury, differentiate among actionable causes, and optimize therapy.
The standard protocols for post-transplant monitoring rely on late-trailing indicators of graft function or painful, expensive, and invasive surveillance biopsies. These tests may not indicate imminent rejection until the allograft is significantly damaged, leaving clinicians and patients fewer options to improve organ health before more severe complications occur.
Transplant Genomics’ extensive development pipeline includes non-invasive diagnostic and predictive tests for kidney and liver graft dysfunction, the use of multiple sample types (e.g. blood and urine) and technology platforms (e.g. NGS, qPCR, and microarrays), companion diagnostics for immunosuppressants, and immune status tests.
Transplant Genomics is a team of passionate and committed scientists, clinicians, laboratory technicians, and business professionals who strive to improve the quality of life for transplant recipients. We are committed to developing innovative tests and technologies that provide an accurate and actionable notice of graft injury, giving transplant care teams the best opportunity to address complications early and preserve organ health and function.
We share a set of core values that infuse everything we do:
We put patients first.
There is a human life behind every specimen we test in the lab. Transplant recipients are our family, friends, and neighbors. We calibrate everything we do by asking, “Will this help get accurate and timely test results into the hands of a clinician and their patient so that they can make the best decisions about their patient’s health?”
We are grounded by science.
We partner with leading research institutions, transplant centers, and higher-education colleges and universities to ensure our work is backed by scientific validity and clinical utility.
We hire talent and nurture our team.
We actively seek out and employ people with demonstrated scientific, operational, and business success who are passionate about improving the quality of life for transplant patients. As a team, we communicate and collaborate, challenge each other, and support each other in fulfilling our mission.
We celebrate our wins.
Helping patients experience better transplant outcomes is a success worth celebrating! We recognize, internally and externally, the strategies, activities, and results that improve patient care.
We are committed to our customers’ success.
We partner with the hospitals and clinics that use our tests, providing the education, tools, and support they need to be successful. We never lose sight of the connection between the tests we offer and the patients who need them.
In 2019, Eurofins Scientific acquired Transplant Genomics as part of its Clinical Diagnostics portfolio of laboratories. Eurofins, through its subsidiaries, is the world leader in food, environment, pharmaceutical, and cosmetic products testing, and in agroscience CRO services. Eurofins is also one of the global independent market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences, and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty esoteric and molecular clinical diagnostic testing in Europe and the USA.
With over 50,000 staff in over 50 countries, operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin, and purity of biological substances and products, as well as for innovative clinical diagnostics. Eurofins’ objective is to provide its customers with high-quality services, accurate results on time, and expert advice by its highly qualified staff.
It was late at night, and Stan was violently ill. His wife quickly threw him in the car and sped to their local hospital outside of Boston. Counting every mile, Stan didn’t know if he would make it.
His head was pounding. He was scared about his blood pressure. It had been 6 years since Stan’s kidney transplant, and this wasn’t the first time he had been sick. Shortly after his transplant, Stan had realized that his doctors were essentially flying blind, waiting for him to get sick then reacting with medicines and biopsies. He could be in rejection right now and had no idea.
That’s when Stan started researching. He found an article on biomarkers in transplantation that was eye opening. But none of this new knowledge had yet been applied to keeping kidney transplant patients healthy. So he called Dr. Michael Abecassis, a leading doctor in the transplant field.
It turned out that Dr. Abecassis and colleague Dr. Dan Solomon had been working for the past 10 years to create a noninvasive alternative to a surveillance biopsy. Through the use of genomics, they were developing a test that measures biomarkers in your blood to reveal what is happening inside of you.
Stan asked Dr. Abecassis about using this genomic test on him. His creatinine had been slowly rising over the past months and he didn’t know if he should be worried about rejection. Using their blood-based test, the results came back showing no signs of rejection in Stan’s blood. His doctors were able to intervene before his precious donated kidney was damaged, and without another biopsy.
Stan had spent his career in the biotechnology executive as a serial entrepreneur, and had retired years before. But knowing how this test could change the lives of thousands of transplant patients, Stan felt compelled to return to work to find a solution to get a noninvasive genomic test to the public. He asked the doctors if he could help them build a company and a properly certified laboratory to make these tests accessible to all.
Stan Rose, Dr. Michael Abecassis, and Dr. Dan Salomon started Transplant Genomics Inc. (TGI), a molecular diagnostics company committed to improving organ transplant outcomes through the use of noninvasive genetic tests to give an early warning sign as to whether or not a patient might be silently rejecting – early enough to intervene with proactive corrective action so that patients could live in peace about their kidney’s health.
His head was pounding. He was scared about his blood pressure. It had been 6 years since Stan’s kidney transplant, and this wasn’t the first time he had been sick. Shortly after his transplant, Stan had realized that his doctors were essentially flying blind, waiting for him to get sick then reacting with medicines and biopsies. He could be in rejection right now and had no idea.
That’s when Stan started researching. He found an article on biomarkers in transplantation that was eye opening. But none of this new knowledge had yet been applied to keeping kidney transplant patients healthy. So he called Dr. Michael Abecassis, a leading doctor in the transplant field.
It turned out that Dr. Abecassis and colleague Dr. Dan Solomon had been working for the past 10 years to create a noninvasive alternative to a surveillance biopsy. Through the use of genomics, they were developing a test that measures biomarkers in your blood to reveal what is happening inside of you.
Stan asked Dr. Abecassis about using this genomic test on him. His creatinine had been slowly rising over the past months and he didn’t know if he should be worried about rejection. Using their blood-based test, the results came back showing no signs of rejection in Stan’s blood. His doctors were able to intervene before his precious donated kidney was damaged, and without another biopsy.
Stan had spent his career in the biotechnology executive as a serial entrepreneur, and had retired years before. But knowing how this test could change the lives of thousands of transplant patients, Stan felt compelled to return to work to find a solution to get a noninvasive genomic test to the public. He asked the doctors if he could help them build a company and a properly certified laboratory to make these tests accessible to all.
Stan Rose, Dr. Michael Abecassis, and Dr. Dan Salomon started Transplant Genomics Inc. (TGI), a molecular diagnostics company committed to improving organ transplant outcomes through the use of noninvasive genetic tests to give an early warning sign as to whether or not a patient might be silently rejecting – early enough to intervene with proactive corrective action so that patients could live in peace about their kidney’s health.
